DOL:TSXDollarama Inc. Analysis
Data as of 2026-03-10 - not real-time
CA$197.44
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Dollarama’s stock is trading at C$197.44, well above its DCF‑derived fair value of roughly C$115 and sporting a trailing PE of 42 and a PB of 41, indicating a pronounced premium. Revenue is expanding at a robust 22% year‑over‑year and margins remain healthy (gross ~46%, operating ~23%), while the dividend yield sits at a modest 0.21% with an 8.7% payout ratio, suggesting ample room for sustainability. Technically, the price sits just above the 20‑day (C$195.19) and 50‑day (C$195.69) SMAs, the RSI is neutral at 53, and the MACD histogram is modestly positive, supporting a slight bullish bias, though the stock faces a clear support line at C$185.89 and resistance near C$203.50.
The company carries an exceptionally high debt‑to‑equity ratio (>400) and a beta of only 0.12, translating to low market‑risk sensitivity but heightened balance‑sheet vulnerability. Volatility over the past 30 days is around 22%, and the consumer‑defensive sector generally offers low to medium risk, while geographic exposure to Canada and parts of Latin America introduces a medium‑level geographic and currency risk. Upcoming Q4 FY2026 earnings on March 24 could act as a catalyst, and while analysts maintain a “Buy” consensus with a median target of C$218 (≈7% upside), the current valuation gap suggests caution. The prudent stance is a neutral‑to‑hold position across horizons, awaiting clearer earnings momentum and any deleveraging progress.
The company carries an exceptionally high debt‑to‑equity ratio (>400) and a beta of only 0.12, translating to low market‑risk sensitivity but heightened balance‑sheet vulnerability. Volatility over the past 30 days is around 22%, and the consumer‑defensive sector generally offers low to medium risk, while geographic exposure to Canada and parts of Latin America introduces a medium‑level geographic and currency risk. Upcoming Q4 FY2026 earnings on March 24 could act as a catalyst, and while analysts maintain a “Buy” consensus with a median target of C$218 (≈7% upside), the current valuation gap suggests caution. The prudent stance is a neutral‑to‑hold position across horizons, awaiting clearer earnings momentum and any deleveraging progress.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish MACD and price above short‑term SMAs
- Support level near C$185.9 limiting downside
- Overvaluation relative to DCF and high multiples
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Strong revenue growth and margin expansion
- Elevated debt‑to‑equity ratio posing balance‑sheet risk
- Upcoming earnings release could clarify valuation gap
Long Term
> 3 yearsNeutral
Model confidence: 4/10
Key Factors
- Sustainable dividend despite low yield
- Defensive consumer sector offering stability
- Premium valuation may compress unless growth accelerates
Key Metrics & Analysis
Financial Health
Revenue Growth22.20%
Profit Margin18.59%
P/E Ratio42.0
ROE102.25%
ROA15.65%
Debt/Equity415.13
P/B Ratio41.6
Op. Cash FlowCA$1.7B
Free Cash FlowCA$1.1B
Technical Analysis
TrendNeutral
RSI53.2
SupportCA$185.89
ResistanceCA$203.50
MA 20CA$195.19
MA 50CA$195.69
MA 200CA$190.53
MACDBullish
VolumeStable
Fear & Greed Index76.18
Valuation
Fair ValueCA$115.52
Target PriceCA$212.06
Upside/Downside7.41%
GradeOvervalued
TypeGrowth
Dividend Yield0.21%
Risk Assessment
Beta0.12
Volatility21.66%
Sector RiskLow
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.